A method for determining the probability that a subject will suffer adverse effects in response to a nicotinic cholinergic receptor agonist drug-based therapy, wherein said adverse effects lead to the withdrawal of said therapy or to a reduction of the usual therapeutic dose of the drug used in said therapy, said method comprises determining in a biological sample of said subject at least one allele of one or more of single-nucleotide polymorphisms (SNPs) rs9479757, rs477292, rs495491, rs3778151, rs7930792, rs12423809, rs4251417, rs7146, rs763132, rs4474069 and rs1183035,, wherein - the presence of at least one A allele of SNP rs9479757, - the presence of at least one A allele of SNP rs477292, - the presence of at least one C allele of SNP rs495491, - the presence of at least one C allele of SNP rs3778151, - the presence of at least one C allele of SNP rs7930792, - the presence of at least one C allele of SNP rs12423809, - the presence of at least one A allele of SNP rs4251417, - the presence of at least one T allele of SNP rs7146, - the presence of at least one T allele of SNP rs763132, - the presence of at least one C allele of SNP rs4474069, and/or - the presence of at least one T allele of SNP rs1183035, is indicative that said subject has a high probability of suffering adverse effects in response to said nicotinic cholinergic receptor agonist drug-based therapy that lead to the withdrawal of said therapy or to a reduction of the usual therapeutic dose of the drug used in said therapy; or, alternatively, - the presence of at least one G allele of SNP rs9479757, - the presence of at least one G allele of SNP rs477292, - the presence of at least one T allele of SNP rs495491, - the presence of at least one T allele of SNP rs3778151, - the presence of at least one G allele of SNP rs7930792, - the presence of at least one A allele of SNP rs12423809, - the presence of at least one G allele of SNP rs4251417, - the presence of at least one C allele of SNP rs7146, - the presence of at least one G allele of SNP rs763132, - the presence of at least one T allele of SNP rs4474069, and/or - the presence of at least one C allele of SNP rs1183035, is indicative that said subject has a low probability of suffering adverse effects in response to said nicotinic cholinergic receptor agonist drug-based therapy that lead to the withdrawal of said therapy or to a reduction of the usual therapeutic dose of the drug used in said therapy. - the presence of at least one A allele of SNP rs9479757, - the presence of at least one A allele of SNP rs477292, - the presence of at least one C allele of SNP rs495491, - the presence of at least one C allele of SNP rs3778151, - the presence of at least one C allele of SNP rs7930792, - the presence of at least one C allele of SNP rs12423809, - the presence of at least one A allele of SNP rs4251417, - the presence of at least one T allele of SNP rs7146, - the presence of at least one T allele of SNP rs763132, - the presence of at least one C allele of SNP rs4474069, and/or - the presence of at least one T allele of SNP rs1183035, - the presence of at least one G allele of SNP rs9479757, - the presence of at least one G allele of SNP rs477292, - the presence of at least one T allele of SNP rs495491, - the presence of at least one T allele of SNP rs3778151, - the presence of at least one G allele of SNP rs7930792, - the presence of at least one A allele of SNP rs12423809, - the presence of at least one G allele of SNP rs4251417, - the presence of at least one C allele of SNP rs7146, - the presence of at least one G allele of SNP rs763132, - the presence of at least one T allele of SNP rs4474069, and/or - the presence of at least one C allele of SNP rs1183035,